Physician profile
Edward Costa
NPI 1306169537
$3,231.78
in general payments reported to CMS, 2019-2025
12 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2021: $43.28 · 2022: $1,281 · 2023: $241 · 2024: $567 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819 · Travel and Lodging: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.89 |
| Travel and Lodging | $289.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seapearl East, INC | $2,016.46 | 2019-2022 | |
| Arthrex, INC. | $333.36 | 2024 | |
| Gotham Surgical Solutions & Devices, INC. | $204.44 | 2024-2025 | |
| Horizon Therapeutics Plc | $124.91 | 2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $117.08 | 2024 | Purified Cortrophin Gel |
| Amgen INC. | $116.26 | 2023 | Tavneos |
| Stryker Corporation | $107.07 | 2021-2022 | |
| Treace Medical Concepts, INC. | $104.76 | 2024-2025 | |
| Integra Lifesciences Corporation | $50.08 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $27.60 | 2024 | Collagenase Santyl, Iodosorb Ointment 40g USA, Regranex |
| Dynasplint Systems INC. | $16.33 | 2024 | Dynasplint |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.43 | 2024 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Costa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.